Press release 📈 Stocks 🌍 United States

Palatin Technologies Unveils Preclinical Data for MC4R Agonist PL2001

Palatin Technologies showcased preclinical results for its MC4R-selective peptide programs, highlighting PL2001's potential for once-weekly dosing and reduced side effects, with human trials targeted for 2027.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: PTN → 3/10 (45% confidence).

📊 Affected Assets (1)

PTN
Neutral 🤖 45%
⚡ Intraday 🌍 US · Explicit

The company presents preclinical data showing greater than 100-fold to greater than 200-fold MC4R selectivity, weight-loss efficacy in obese mice, and half-lives of roughly 24 hours in rodents and greater than 168 hours in dogs, with PL2001 selected for first-in-human studies in the first half of 2027. These are supportive pipeline milestones that may lift sentiment, but they are animal and in vitro results without a comparable prior figure being beaten, so no hard fact changes the financial outlook. Clinical data is not expected until the second half of 2027.

Catalysts
  • • Poster presentation at ObesityWeek 2026 on November 14, 2026
  • • PL2001 selected as clinical development candidate with first-in-human studies targeted for the first half of 2027
Risk Factors
  • • All reported data are preclinical (in vitro and animal models) and may not translate to humans
  • • Initial clinical data not anticipated until the second half of 2027

🎯 Key Takeaways

  • PL2001 and other compounds showed greater than 100-fold to greater than 200-fold selectivity for MC4R over MC1R in functional assays.
  • Lipidated peptides demonstrated a half-life of greater than 168 hours in dogs, compared to approximately two hours for non-lipidated peptides.
  • Palatin Technologies has scheduled first-in-human studies for its lead candidate, PL2001, for the first half of 2027.
  • Initial clinical data for the MC4R-selective program is anticipated in the second half of 2027.

📝 Executive Summary

Palatin Technologies presented new preclinical data at ObesityWeek 2026, showcasing its MC4R-selective peptide agonists. The lead candidate, PL2001, demonstrated significant weight-loss efficacy in animal models and a half-life exceeding 168 hours in dogs. The company plans to initiate first-in-human studies for PL2001 in the first half of 2027, with initial clinical data expected in the second half of 2027.

❓ FAQ

Did Palatin report any human trial results?

No. The data presented are preclinical, from laboratory and animal studies. First-in-human studies for the lead candidate PL2001 are targeted for the first half of 2027, with initial clinical data anticipated in the second half of 2027.

What is the key claimed advantage of these compounds?

The compounds show potent MC4R activity with minimal to no MC1R activity, which the company says could substantially reduce or eliminate hyperpigmentation, a known side effect of currently approved MC4R therapies, and the lipidation technology supports once-weekly or less frequent dosing.